🇺🇸 FDA
Patent

US 11655275

Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

granted A61KA61K35/42A61K35/545

Quick answer

US patent 11655275 (Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene) held by Sangamo Therapeutics, Inc. expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K35/42, A61K35/545, A61K38/00